Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6474-6483

  Rai, Ganesha ^a   Sayed, Ahmed A ^b,c   Lea, Wendy A ^a   Luecke, Hans F ^d   Chakrapani, Harinath ^e   Prast Nielsen, Stefanie ^f   Jadhav, Ajit ^g   Leister, William ^a   Shen, Min ^a   Inglese, James ^a   Austin, Christopher P ^a   Keefer, Larry ^e   Arnér, Elias S J ^f   Simeonov, Anton ^a   Maloney, David J ^a   Williams, David L ^b,g   Thomas, Craig J ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b ILLINOIS STATE UNIVERSITY   (United States)

^c Ain Shams University   (Egypt)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISCHISTOSOMAL AGENT; GLUTATHIONE REDUCTASE; NITRIC OXIDE; OXADIAZOLE 2 OXIDE DERIVATIVE; THIOREDOXIN GLUTATHIONE REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; PHARMACOPHORE; SCHISTOSOMIASIS; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MULTIENZYME COMPLEXES; NADH, NADPH OXIDOREDUCTASES; NITRIC OXIDE; OXADIAZOLES; PROTEIN CONFORMATION; RATS; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMICIDES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 70350059120     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901021k     Document Type: Article

References (64)

1. Hotez, P. J.; Brindley, P. J.; Bethony, J. M.; King, C. H.; Pearce, E. J.; Jacobson, J. Helminth infections: the great neglected tropical diseases. J. Clin. Invest. 2008, 118, 1311-1321.
2. Steinmann, P.; Keiser, J.; Bos, R.; Tanner, M.; Utzinger, J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis. 2006, 6, 411-425.
3. van der Werf, M. J.; de Vlas, S. J.; Brooker, S.; Looman, C. W.; Nagelkerke, N. J.; Habbema, J. D.; Engels, D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003, 86, 125-139. (Pubitemid 36561364)
4. King, C. H.; Dangerfield-Cha, M. The unacknowledged impact of chromic schistosomiasis. Chronic Illness 2008, 4, 65-79.
5. Gonnert, R.; Andrews, P. Praziquantel, a new broad spectrum antischistosomal agent. Z. Parasitenk. 1977, 52, 129-150.
6. Hagan, P.; Appleton, C. C.; Coles, G. C.; Kusel, J. R.; Tchuem Tchuenté, L. A. Schistosomiasis control: keep taking the tablets. Trends Parasitol. 2004, 20, 92-97.
7. Fenwick, A.; Webster, J. P. Schistosomiasis: challenges for control, treatment and drug resistance. Curr. Opin. Infect. Dis. 2006, 19, 577-582.
8. 2+ channels targets of Praziquantel action? Int. J. Parasitol. 2004, 35, 1-9.
9. 2+ Channel β Subunits: Subversion of Flatworm Regenerative Polarity. PLoS Neglected Trop. Dis. 2009, 3, e464.
10. Doenhoff, M. J.; Cioli, D.; Utzinger, J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr. Opin. Infect. Dis. 2008, 21, 659-667.
11. Townsend, D. M.; Tew, K. D.; Tapiero, H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57, 145-155.
12. Lillig, C. H.; Holmgren, A. Thioredoxin and related molecules - from biology to health and disease. Antioxid. Redox Signaling 2007, 9, 25-47.
13. Alger, H. M.; Sayed, A. A.; Stadecker, M. J.; Williams, D. L. Molecular and enzymatic characterisation of Schistosoma mansoni thioredoxin. Int. J. Parasitol. 2002, 32, 1285-1292.
14. Angelucci, F.; Miele, A. E.; Boumis, G.; Dimastrogiovanni, D.; Brunori, M.; Bellelli, A. Glutathione reductase and thioredoxin reductase at the crossroad: the structure of Schistosoma mansoni thioredoxin glutathione reductase. Proteins 2008, 72, 936-945. (Pubitemid 352000871)
15. Kuntz, A. N.; Davioud-Charvet, E.; Sayed, A. A.; Califf, L. L.; Dessolin, J.; Arnér, E. S.; Williams, D. L. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 2007, 4, e206. (Pubitemid 46998624)
16. Simeonov, A.; Jadhav, A.; Sayed, A. A.; Wang, Y.; Nelson, M. E.; Thomas, C. J.; Inglese, J.; Williams, D. L.; Austin, C. P. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Neglected Trop. Dis. 2008, 2, e127.
17. Lea, W. A.; Jadhav, A.; Rai, G.; Sayed, A. A.; Cass, C. L.; Inglese, J.; Williams, D. L.; Austin, C. P.; Simeonov, A. A 1536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. Assay Drug Dev. Technol. 2008, 6, 551-555.
18. Austin, C. P.; Brady, L. S.; Insel, T. R.; Collins, F. S. NIH Molecular Libraries Initiative. Science 2004, 306, 1138.
19. Inglese, J.; Auld, D. S.; Jadhav, A.; Johnson, R. L.; Simeonov, A.; Yasgar, A.; Zheng, W.; Austin, C. P. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11473-11478.
20. Sayed, A. A.; Simeonov, A.; Thomas, C. J.; Inglese, J.; Austin, C. P.;Williams, D. L. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nature Med. 2008, 4, 407-412.
21. Nwaka, S.; Hudson, A. Innovative lead discovery strategies for tropical diseases. Nature Rev. Drug Discovery 2006, 5, 941-955. (Pubitemid 44660607)
22. Gasco, A.; Fruttero, R.; Sorba, G.; Di Stilo, A.; Calvino, R. NO donors: focus on furoxan derivatives. Pure Appl. Chem. 2004, 76, 973-981.
23. Gasco, A.; Schoenafinger, K. The NO-releasing heterocycles. In Nitric Oxide Nonors;Wang, G., Cai, T. B., Taniguchi, N., Eds.;Wiley-VCH: Weinheim, Germany, 2005.
24. Lundberg, J. O.; Weitzberg, E.; Gladwin, M. T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nature Rev. Drug Discovery 2008, 7, 156-167.
25. Paolocci, N.; Jackson, M. I.; Lopez, B. E.; Miranda, K.; Tocchetti, C. G.; Wink, D. A.; Hobbs, A. J.; Fukuto, J. M. The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the janus face of NO. Pharm. Ther. 2007, 113, 442-458.
26. Ignarro, L. J. Nitric Oxide Biology and Pathobiology; Academic Press; San Diego, 2000.
27. Medana, C.; Ermondi, G.; Fruttero, R.; Di Stilo, A.; Ferretti, C.; Gasco, A. Furoxans as nitric oxide donors. 4-Phenyl-3-furoxan-carbonitrile: thiol-mediated nitric oxide release and biological evaluation. J. Med. Chem. 1994, 37, 4412-4416.
28. 2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans. J. Med. Chem. 2007, 50, 5003-5011.
29. Turnbull, C. M.; Cena, C.; Fruttero, R.; Gasco, A.; Rossi, A. G.; Megson, I. L. Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. Br. J. Pharmacol. 2006, 148, 517-526.
30. Sorba, G.; Galli, U.; Cena, C.; Fruttero, R.; Gasco, A.; Morini, G.; Adami, M.; Coruzzi, G.; Brenciaglia, M. I.; Dubini, F. A new furoxan NO-donor rabeprazole derivative and related compounds. ChemBioChem 2003, 4, 899-903. (Pubitemid 37185705)
31. Brunet, L. R. Nitric oxide in parasitic infections. Int. Immunopharmacol. 2001, 1, 1457-1467.
32. Colasanti, M.; Gradoni, L.; Mattu, M.; Persichini, T.; Salvati, L; Venturini, G.; Ascenzi, P. Molecular basis for the anti-parasitic effect on NO. Int. J. Mol. Med. 2002, 9, 131-134.
33. Rivero, A. Nitric oxide: an antiparasitic molecule of invertebrates. Trends Parasitol. 2006, 22, 219-225.
34. James, S. L.; Glaven, J. Macrophage cytotoxicity against schistosomula of Schistosoma mansoni involves arginine-dependent production of reactive nitrogen intermediates. J. Immunol. 1989, 143, 4208-4212. (Pubitemid 20012616)
35. Amri, M.; Aissa, S. A.; Belguendouz, H.; Mezioug, D.; Touil-Boukoffa, C. In vitro antihydatic action of IFN- is dependent on the nitric oxide pathway. J. Interferon Cytokine Res. 2007, 27, 781-787.
36. Magez, S.; Radwanska, M.; Drennan, M.; Fick, L.; Baral, T. N.; Allie, N.; Jacobs, M.; Nedospasov, S.; Brombacher, F.; Ryffel, B.; De Baetselier, P. Tumor Necrosis Factor (TNF) Receptor-1 (TNFp55) Signal Transduction and Macrophage-Derived Soluble TNF are Crucial for Nitric Oxide-Mediated Trypansosoma congolense Parasite Killing. J. Infect. Dis. 2007, 196, 954-962.
37. Winberg, M. E.; Rasmusson, B.; Sundqvist, T. Leishmania donovani: inhibition of phagosomal maturation is rescued by nitric oxide in macrophages. Exp. Parasitol. 2007, 117, 165-170.
38. López-Jaramillo, P.; Ruano, C.; Rivera, J.; Terán, E.; Salazar-Irigoyen, R.; Esplugues, J. V.; Moncada, S. Treatment of cutaneous leishmaniasis with nitric oxide donor. Lancet 1998, 351, 1176-1177. (Pubitemid 28171824)
39. Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. W.; Niyomrattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.; Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E. PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release. Science 2008, 322, 1392-1395.
40. Mady, C.; Ianni, B. M.; de Souza, J. L., Jr. Benznidazole and Chagas disease: can an old drug be the answer to an old problem? Expert Opin. Investig. Drugs 2008, 17, 1427-1433.
41. Wilkinson, S. R.; Taylor, M. C.; Horn, D.; Kelly, J. M.; Cheeseman, I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5022-5027.
42. Nims, R. W.; Darbyshire, J. F.; Saavedra, J. E.; Christodoulou, D.; Hanbauer, I.; Cox, G. W.; Grisham, M. B.; Laval, F.; Cook, J. A.; Krishna, M. C.; Wink, D. A. Colorimetric methods for the determination of nitric oxide concentration in neutral aqueous solutions. Methods 1995, 7, 48-55.
43. Akaike, T.; Yoshida, M.; Miyamoto, Y.; Sato, K.; Kohno, M.; Sasamoto, K.; Miyazaki, K.; Ueda, S.; Maeda, H. Antagonistic action of imidazolineoxyl N-Oxides against endothelium-derived relaxing factor/NO through a radical reaction. Biochemistry 1993, 32, 827-832. (Pubitemid 23059363)
44. Rai, G.; Thomas, C. J.; Leister, W.; Maloney, D. J. Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents. Tetrahedron Lett. 2009, 50, 1710-1713.
45. Lei, S. Z.; Pan, Z. H.; Aggarwal, S. K.; Chen, H. S.; Hartman, J.; Sucher, N. J.; Lipton, S. A. Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron 1992, 8, 1087-1099.
46. Stamler, J. S.; Simon, D. I.; Osborne, J. A.; Mullins, M. E.; Jaraki, O.; Michel, T.; Singel, D. J.; Loscalzo, J. S-Nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 444-448.
47. Becker, K.; Savvides, S. N.; Keese, M.; Schirmer, R. H.; Karplus, P. A. Enzyme inactivation through sulfhydryl oxidation by physiologic NO-carriers. Nat. Struct. Biol. 1998, 5, 267-271.
48. Badorff, C.; Fichtlscherer, B.; Rhoads, R. E.; Zeiher, A. M.; Muelsch, A.; Dimmeler, S.; Knowlton, K. U. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation. Circulation 2000, 102, 2276-2281.
49. Saura, M.; Zaragoza, C.; McMillian, A.; Quick, R. A.; Hohenadl, C.; Lowenstein, J. M.; Lowenstein, C. J. An antiviral mechanism of nitric oxide: Inhibition of a viral protease. Immunity 1999, 10, 21-28. (Pubitemid 29077380)
50. Xian, M.; Wang, Q. M.; Chen, X.; Wang, K.; Wang, P. G. S-Nitrosothiols as novel, reversible inhibitors of human rhinovirus 3C protease. Bioorg. Med. Chem. Lett. 2000, 10, 2097-2100.
51. Jaffrey, S. R.; Snyder, S. H. The biotin switch method for the detection of S-nitrosylated proteins. Sci. STKE 2001, 86, pl1.
52. Jaffrey, S. R.; Fang, M.; Snyder, S. H. Nitrosopeptide Mapping: A Novel Methodology Reverses S-nitrosylation of Dexras1 on a Single Cysteine Residue. Chem. Biol. 2002, 9, 1329-1335.
53. Chakrapani, H.; Bartberger, M. D.; Toone, E. J. C-Nitroso Donors of Nitric Oxide. J. Org. Chem. 2009, 74, 1450-1453.
54. Oballa, R. M.; Truchon, J.-F.; Bayly, C. I.; Chauret, N.; Day, S.; Crane, S.; Berthelette, C. A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. Bioorg. Med. Chem. Lett. 2007, 17, 998-1002.
55. Fontijn, A.; Sabadell, A. J.; Ronco, R. J. Homogeneous Chemiluminescent Measurement of Nitric Oxide with Ozone. Anal. Chem. 1970, 42, 575-579.
56. Hatfield, D. L.; Carlson, B. A.; Xu, X. M.; Mix, H.; Gladyshev, V. N. Selenocysteine incorporation machinery and the role of selenoproteins in development and health. Prog. Nucleic Acid Res. Mol. Biol. 2006, 81, 97-142.
57. Kryukov, G. V.; Gladyschev, V. N. The prokaryotic selenoproteome. EMBO Rep. 2004, 5, 538-543.
58. Benesch, R. E.; Benesch, R. The acid strength of the SH group in cysteine and related compounds. J. Am. Chem. Soc. 1955, 77, 5877-5881.
59. Huber, R. E.; Criddle, R. S. Comparison of the chemical properties of selenocysteine and selenocystine with their sulfur analogs. Arch. Biochem. Biophys. 1967, 122, 164-173.
60. Johansson, L.; Gafvelin, G.; Arnér, E. S. J. Selenocysteine in proteins;properties and biotechnological use. Biochem. Biophys. Acta. 2005, 1726, 1-13.
61. Castellano, S.; André;s, A. M.; Bosch, E.; Bayes, M.; Guigó, R.; Clark, A. G. Low Exchangeability of Selenocysteine, the 21st Amino Acid, in Vertebrate Proteins. Mol. Biol. Evol. 2009, 26, 2031-2040.
62. Hickey, J. L.; Ruhayel, R. A.; Barnard, P. J.; Baker, M. V.; Berners-Price, S. J.; Filipovska, A. Mitochondria-Targeted Chemotherapeutics: The Rational Design of Gold(I) N-Heterocyclic Carbene Complexes that are Selectively Toxic to Cancer Cells and Target Protein Selenols in Preference to Thiols. J. Am. Chem. Soc. 2008, 130, 12570-12571.
63. Anestål, K.; Prast-Nielsen, S.; Cenas, N.; Arnér, E. S. J. Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells. PLoS One 2008, 3, e1846.
64. Zhong, L.; Arnér, E. S. J.; Ljung, J.; Aslund, F.; Holmgren, A. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue. J. Biol. Chem. 1998, 273, 8581-8591.